Boston Partners’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Boston Partners’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-380,143	Closed	-$1.41M	–	790
2017 Q4	$1.41M	Hold	380,143	–	–	﹤0.01%	699
2017 Q3	$1.55M	Hold	380,143	–	–	﹤0.01%	694
2017 Q2	$1.41M	Buy	+380,143	New	+$1.51M	﹤0.01%	684

Boston Partners's CASC Position: Q1 2018 in Review

Boston Partners sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 380,143 shares — an estimated $1.41M sold.

Boston Partners first reported a position in CASC in Q2 2017 and held it in 3 quarters. The position peaked at $1.55M in Q3 2017. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.

Boston Partners reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Boston Partners sold 380,143 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $1.41M.
Boston Partners first reported a position in Cascadian Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
Boston Partners's Cascadian Therapeutics, Inc. position peaked at $1.55M in Q3 2017.
1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.

Based on Boston Partners's 13F filing for Q1 2018, filed 4 May 2018.